Updated Jul 16, 2026
Boyce Sarah has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.81M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-27 | RNAM | Avidity Biosciences, Inc. | D — Derivative transaction | 474.9K | — | |
| 2026-01-23 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale [10b5-1] | 8.0K | $72.45 | $579K |
| 2026-01-23 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale [10b5-1] | 6.4K | $72.45 | $463K |
| 2025-09-05 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale | 50.0K | $49.95 | $2.50M |
| 2025-09-05 | RNAM | Avidity Biosciences, Inc. | M — Option exercise | 50.0K | $1.24 | $62K |
| 2025-08-28 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale | 25.0K | $49.39 | $1.23M |
| 2025-08-28 | RNAM | Avidity Biosciences, Inc. | M — Option exercise | 25.0K | $1.24 | $31K |
| 2024-12-19 | RNAM | Avidity Biosciences, Inc. | S — Open-market sale [10b5-1] | 31.9K | $32.66 | $1.04M |
Boyce Sarah is a corporate insider — currently tracked as Director of Contineum Therapeutics, Inc. (CTNM). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($5.81M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Boyce Sarah profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.